Lindus Health Raises $55M to Revolutionize Clinical Trials with AI

London-based startup Lindus Health, backed by billionaire investor Peter Thiel, has secured a $55 million Series B funding round to transform the clinical trial industry. The announcement comes as artificial intelligence (AI) continues to reshape drug discovery and development, intensifying the need for streamlined, efficient clinical trial processes.

Founded in 2021, Lindus Health offers an end-to-end platform to simplify and accelerate clinical trials, leveraging automation and machine learning to optimize trial design, recruitment, and data collection.

Revolutionizing the CRO Model

Positioning itself as the “anti-CRO” (contract research organization), Lindus Health aims to overhaul the traditional $82 billion CRO market by offering a fully integrated solution. The platform’s standout feature is a protocol generation tool, trained on historical data, that drafts trial protocols—one of the most time-intensive steps in the process.

In addition to technology, Lindus provides the staff needed for trials, including medics, technologists, and regulatory experts, delivering a comprehensive clinical trial experience.

To date, the company has facilitated trials for conditions such as asthma, diabetes, chronic fatigue syndrome, and weight management across Europe and the U.S., focusing on under-researched, complex conditions.

Addressing the AI Drug Discovery Bottleneck

With the rise of AI in drug discovery, clinical trials remain a critical bottleneck in bringing potential treatments to market. As AI companies generate hypotheses and drug targets, trials are essential for validation.

“Frankly, all these AI drug discovery companies are not going to have the impact they deserve unless we fix this bottleneck in clinical trials,” said Meri Beckwith, co-founder of Lindus Health.

The company’s mission is to help biotech companies test and iterate more efficiently, enabling faster and safer delivery of life-saving treatments.

Scaling Up and Expanding Horizons

With total funding now exceeding $80 million, Lindus plans to:

• Relocate its global headquarters from the U.K. to the U.S.
• Expand into more complex clinical trial types.
• Invest in its go-to-market teams.
• Enhance real-time data analysis and integrate with third-party tools like electronic medical records.

Co-founder Beckwith sees even greater potential for AI in Lindus’ future, saying, “We’re just scratching the surface of what we can do with AI.”

Investors and the Road Ahead

This Series B round, led by Balderton Capital, saw participation from Creandum, Firstminute, Seedcamp, and Visionaries Club. Lindus’ innovative approach to clinical trials could significantly accelerate the timeline for new treatments, making it a critical player in the evolving biotech ecosystem.

With its ambitious expansion plans and ongoing investment in cutting-edge AI, Lindus Health is poised to redefine the clinical trial landscape in the years to come.